Sugi Predict

Sugi Predict / Targets / RICTOR

RICTOR

Rapamycin-insensitive companion of mTOR · Q6R327 · RICTOR on Sugi Atlas →

11,493 patent compounds predicted against RICTOR, 8,818 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL446433 SCHEMBL446433 0.49 10/20
SCHEMBL446434 SCHEMBL446434 0.49 10/20
SCHEMBL443760 SCHEMBL443760 0.66 9/20
SCHEMBL446729 SCHEMBL446729 0.50 8/20
SCHEMBL446730 SCHEMBL446730 0.50 8/20
SCHEMBL336390 SCHEMBL336390 0.57 7/20
SCHEMBL336770 SCHEMBL336770 0.55 6/20
SCHEMBL413932 SCHEMBL413932 0.54 6/20
SCHEMBL443148 SCHEMBL443148 0.54 6/20
SCHEMBL336266 SCHEMBL336266 0.56 5/20
SCHEMBL442089 SCHEMBL442089 0.46 4/20
SCHEMBL135776 SCHEMBL135776 1.00 3/20
SCHEMBL138388 SCHEMBL138388 1.00 3/20
SCHEMBL137228 SCHEMBL137228 0.90 3/20
SCHEMBL138631 SCHEMBL138631 0.88 3/20
SCHEMBL138867 SCHEMBL138867 0.85 3/20
SCHEMBL138628 SCHEMBL138628 0.85 3/20
SCHEMBL481136 SCHEMBL481136 0.85 3/20
SCHEMBL137103 SCHEMBL137103 0.84 3/20
SCHEMBL138732 SCHEMBL138732 0.83 3/20

Clinical trials — most relevant to RICTOR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA PHASE4COMPLETED
Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris PHASE4UNKNOWN
HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial PHASE4NOT_YET_RECRUITING
Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency PHASE3UNKNOWN
An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS PHASE3UNKNOWN
CVL237 Tablets for APDS/PASLI PHASE2/PHASE3UNKNOWN
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma PHASE3COMPLETED
Everolimus trIal for Advanced prememopausaL Breast Cancer Patients PHASE2UNKNOWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma PHASE2COMPLETED
A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma PHASE2COMPLETED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI PHASE2COMPLETED
Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas PHASE2COMPLETED
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) PHASE2ACTIVE_NOT_RECRUITING
Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer PHASE2COMPLETED
A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa PHASE2COMPLETED
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations PHASE2COMPLETED
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO) PHASE2ACTIVE_NOT_RECRUITING
A Trial of Ipatasertib in Combination With Atezolizumab PHASE1/PHASE2ACTIVE_NOT_RECRUITING
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children PHASE2COMPLETED
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1WITHDRAWN
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer PHASE1COMPLETED
Rapalog Pharmacology (RAP PAC) Study PHASE1RECRUITING
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy PHASE1UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation nanAPPROVED_FOR_MARKETING
Everolimus TDM to Predict Long Term Toxicity nanUNKNOWN
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) nanRECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a RICTOR binder may also engage these)

ProteinNameSimilarity
Q6QI06 — 1.000 Q6QI06 →
Q8IWV8 — 0.982 Q8IWV8 →
USP9X Ubiquitin carboxyl-terminal hydrolase 9X 0.979 landscape →
Q5ZJZ6 — 0.978 Q5ZJZ6 →
Q56A27 — 0.976 Q56A27 →
O35841 — 0.976 O35841 →
Q7TPD0 — 0.976 Q7TPD0 →
O00507 — 0.975 O00507 →
Q8BHL5 — 0.975 Q8BHL5 →
Q96JJ3 — 0.975 Q96JJ3 →
Q5R644 — 0.974 Q5R644 →
Q8IZQ1 — 0.974 Q8IZQ1 →
Q1LVW0 — 0.974 Q1LVW0 →
Q6WKZ8 — 0.973 Q6WKZ8 →
Q9R1D7 — 0.973 Q9R1D7 →
Q5ZMW3 — 0.973 Q5ZMW3 →
Q6GQD0 — 0.972 Q6GQD0 →
B1MTK1 — 0.972 B1MTK1 →
P0C7A6 — 0.971 P0C7A6 →
PDS5A Sister chromatid cohesion protein PDS5 homolog A 0.971 landscape →
Q8BWQ6 — 0.971 Q8BWQ6 →
Q6DIE2 — 0.971 Q6DIE2 →
Q7TMY8 — 0.971 Q7TMY8 →
Q9H3E2 — 0.971 Q9H3E2 →
Q68E01 — 0.971 Q68E01 →
Q9Y5W8 — 0.971 Q9Y5W8 →
GTF3C3 General transcription factor 3C polypeptide 3 0.970 landscape →
Q7Z3V4 — 0.970 Q7Z3V4 →
Q9SV20 — 0.970 Q9SV20 →
HUWE1 E3 ubiquitin-protein ligase HUWE1 0.970 landscape →